Results 101 to 110 of about 1,494 (190)
Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with dismal outcomes for which no standard therapy exists.
Hogdal, Leah J. +16 more
core +1 more source
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare and often life-threatening complex hematologic malignancy that can commonly infiltrate the skin, lymph nodes, central nervous system, and bone marrow.
Haripriya Andanamala +2 more
doaj +1 more source
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) constitutes a rare and aggressive malignancy originating from plasmacytoid dendritic cells (pDCs) with a primarily cutaneous tropism followed by dissemination to the bone marrow and other organs.
Chteinberg, Emil, +43 more
core +1 more source
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
The interleukin-3 receptor alpha chain (IL-3R), more commonly referred to as CD123, is widely overexpressed in various hematological malignancies, including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia, hairy cell leukemia, Hodgkin ...
Testa, Castelli, Pelosi
core +1 more source
Blastic Plasmacytoid Dendritic Cell Neoplasm–Current Insights
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare clonal hematologic malignancy of plasmacytoid dendritic cell precursors. The presentation and clinical course of BPDCN is widely heterogeneous and was most recently categorized as a distinct ...
Venugopal, Sangeetha +4 more
core +1 more source
Background: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an underdiagnosed rare disease with poor outcomes and limited treatment options.
Attardi, Enrico +42 more
core +1 more source
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [PDF]
openaire +1 more source
Case Report: Blastic plasmacytoid dendritic cell neoplasm mimicking systemic lymphoma: a multidisciplinary diagnostic challenge. [PDF]
Lv B, Rong Q, Li Y, Zhang D.
europepmc +1 more source

